Lirum Therapeutics Announces Positive LX-101 Data for Presentation at AACR 2026

Lirum Therapeutics Announces Positive LX-101 Data Selected for Presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. 

Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing targeted therapeutics to treat debilitating diseases in oncology and autoimmune spaces. Founded in 2021, the company focuses on developing and commercializing targeted therapeutics to treat debilitating diseases in oncology and autoimmune spaces. 

Announcement of new LX-101 data in Ewing sarcoma has been selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego. LX-101 is a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), currently being developed in oncology and autoimmune indications. 

According to Towards Healthcare, the Patient-Derived Xenografts/PDX Models Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 696.91 million in 2026 to approximately USD 2230.79 million by 2035, representing a compound annual growth rate (CAGR) of 13.8% from 2026 to 2035. Growth is driven by the regulatory agencies increasingly accepting PDX efficacy and biomarker data in Investigational New Drug (IND) filings, helping to reduce late-stage clinical trial failures and shift toward targeted therapies and immuno-oncology, which has made PDX models the gold standard for predicting human tumor responses. 

About Ewing Sarcoma 

The company has strong ties to the IGF-1R signaling pathway, which includes DNA-level gene fusions that affect IGF-1R signaling, providing a strong scientific and clinical rationale for LX-101 in this indication.  

It is a rare, aggressive cancer that forms in bones or surrounding soft tissues, primarily affecting children, teens, and young adults. It develops in the pelvis, ribs, long bones of the legs and arms, or surrounding soft tissues, most commonly affecting children, adolescents, and young adults. Usually starts in the bones but can begin in soft tissues. It is a common bone cancer in children and young adults, accounting for roughly 1% of childhood cancers. 

A recent report by Towards Healthcare highlights that the Patient-Derived Xenografts/PDX Models Market is witnessing growth due to the market being driven by the shift towards precision medicine, rising cancer rates, and the need to reduce high failure rates in clinical drug development.  

The traditional system PDX model, acting as an industry safeguard by faithfully preserving human tumor heterogeneity and the original microenvironment, which allows more precise target validation and efficacy profiling and screening, accounts for over half of market revenue, followed by biomarker identification and academic research.